After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by ...

ABU DHABI, 10th February, 2026 (WAM) -- The Global Institute for Disease Elimination (GLIDE) on Tuesday announced the winners of its Falcon Awards for Disease Elimination Integration Edit, recognising ...

The year 2025 will be remembered in Armenia’s recent history as one of bold ambition, but also of exposed vulnerabilities.

Vector is responding to profound shifts in the software and automotive industries with a comprehensive strategic and ...

Market observers are awaiting detailed financial data, expected to be released in Japan Tobacco's annual results this February. These figures will provide the first concrete evidence of how much the ...

According to Vector, both the software and automotive sectors are undergoing a fundamental shift. Software and AI are ...

Studies of Hunter and Hurler syndromes on hold ...

In principle, the goal of lymphocyte engineering is to pharmacologically enhance the function of the immune system, including specifying antigen recognition, improving lymphocyte survival, augmenting ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...

A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.

AI economics are exposing a gap between what people think the cloud costs and what the cloud actually costs. A North American manufacturer spent most of 2024 and early 2025 doing what many innovative ...